[5] It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA).

That month, it also received a patent covering "proprietary polymer combinations (as used in AcuForm tablets) to create improved formulations of existing drugs.

[10] In April 2006, Depomed entered a license agreement with Esprit Pharma over Proquin XR, a "prolonged-release formulation of ciprofloxacin hydrochloride" to treat urinary tract infections.

[18] For $240 million, DL BioPharma purchased the royalty rights to Depomed's Glumetza, a type 2 diabetes drug, in October 2013.

[22] At the time, Depomed had five pain treatments on the market, including Nucynta, considered its flagship product.

[23] In early April 2016, activist investor Starboard Value accused DepoMed of being "unfriendly to shareholders," noting in part a plan to relocate from California to Delaware.

In March 2017, more activity by activist investors resulted in CEO Jim Schoeneck being replaced by Arthur Higgins.

[26] Nucynta's rights were sold to Collegium Pharmaceutical, for $10 million upfront and royalty payments until December 2022.

[29] By 2010 the company was based in Menlo Park, California, and was known for improving "the bio-availability of generic drugs by using polymers usually used in the food and cosmetics industry to reduce side effects and lower the doses necessary for oral medications.

[4] In January 2011, Gralise once-daily (gabapentin extended release) was approved by the US FDA for the treatment of postherpetic neuralgia.

On January 15, 2015, Depomed announced the acquisition of the Tapentadol(Nucynta) franchise from Janssen Pharmaceutica for US$1,050,000,000 in cash.

After Hurricane Maria in 2017 the company faced major shortages of the drug due to the manufacturing plant location in Puerto Rico.

[34] The company has faced a number of lawsuits related to its marketing of the Nucynta opioid painkiller, with Assertio denying wrongdoing.

[35] In March 2019, Assertio won a dismissal of a lawsuit by shareholders that accused the company of hiding how much its growth was dependent on Nucynta marketing for off-label purposes.